Protein test may spot preeclampsia risk in High-Risk pregnancies
NCT ID NCT04319341
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study examined whether measuring a protein called ADAMTS13 in early pregnancy can help predict preeclampsia in women with antiphospholipid antibody syndrome (APS). Researchers analyzed stored blood samples from 513 women in the NOH-APS cohort who became pregnant after their APS diagnosis. The goal was to see if ADAMTS13 activity, antigen levels, or autoantibodies were linked to later development of preeclampsia or related complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a blood test that helps predict preeclampsia risk early in pregnancy for women with antiphospholipid antibody syndrome.
- What could go wrong
- This is an observational study using stored samples, not a treatment trial. It may not prove that ADAMTS13 directly causes or prevents preeclampsia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID ANTIBODY SYNDROME IN PREGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nîmes - Hôpital Universitaire Carémea
Nîmes, 30029, France